<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172194</url>
  </required_header>
  <id_info>
    <org_study_id>19-PT-02</org_study_id>
    <nct_id>NCT04172194</nct_id>
  </id_info>
  <brief_title>Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas</brief_title>
  <official_title>Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The association of transcatheter arterial chemotherapy infusion (TAC) with
      percutaneous ablation (PT) has been introduced as a method to increase the ablative zone. The
      aim of this study was to evaluate the efficacy of PT and TAC performed in a single session
      for HCCs between 30 and 50 mm or oligonodular up to 30 mm.

      Methods: Thirty patients with a histologically proven HCC, uninodular between 30 and 50 mm or
      oligonodular (n≤3) up to 30 mm, treatment-naïve and non-metastatic, received combination
      treatment (&quot;PT+TAC group&quot;). A &quot;control&quot; group consisted of 34 patients with uninodular HCC up
      to 30 mm without any poor prognostic criteria treated with PT alone (&quot;PT group&quot;).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2009</start_date>
  <completion_date type="Actual">December 31, 2014</completion_date>
  <primary_completion_date type="Actual">December 31, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>30 minutes</time_frame>
    <description>death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>30 minutes</time_frame>
    <description>relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerance</measure>
    <time_frame>30 minutes</time_frame>
    <description>apparition of complication define by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">64</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>PT Group</arm_group_label>
    <description>patients with hepatocellular carcinoma treated by percutaneous thermoablation alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT+TAC group</arm_group_label>
    <description>patients with hepatocellular carcinoma treated by pecutaneous thermoablation comined in a single session with trans-arterial chemoembolization</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with hepatocellular carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - hepatocellular carcinoma pouved by pathology,

        Exclusion Criteria:

        - metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nice Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

